Table 4.

Neurologic complications and outcomes in pediatric TA-TMA

Moderate or high-risk TA-TMA, % (n) (n = 28)No TA-TMA % (n) (n = 72)P
Neurology consult requested 28.5 (8) 15.3 (11) 0.15 
Clinician concern for seizure 25 (7) 5.6 (4) 0.01 
EEG performed 21.4 (6) 2.8 (2) 0.006 
Seizure captured on EEG 7.1 (2) 1.4 (1) 0.19 
Stroke 0 (0) 1.4 (1) >0.99 
PRES 10.7 (3) 1.4 (1) 0.07 
AMS 50 (14) 18.1 (13) 0.002 
Ophthalmology consult requested 46.4 (13) 33.3 (24) 0.25 
ICU admission/transfer 67.9 (19) 37.5 (27) 0.008 
Intubated 42.9, (12) 9.7 (7) 0.0004 
Expired 32.1 (9) 4.2 (3) 0.0004 
Moderate or high-risk TA-TMA, % (n) (n = 28)No TA-TMA % (n) (n = 72)P
Neurology consult requested 28.5 (8) 15.3 (11) 0.15 
Clinician concern for seizure 25 (7) 5.6 (4) 0.01 
EEG performed 21.4 (6) 2.8 (2) 0.006 
Seizure captured on EEG 7.1 (2) 1.4 (1) 0.19 
Stroke 0 (0) 1.4 (1) >0.99 
PRES 10.7 (3) 1.4 (1) 0.07 
AMS 50 (14) 18.1 (13) 0.002 
Ophthalmology consult requested 46.4 (13) 33.3 (24) 0.25 
ICU admission/transfer 67.9 (19) 37.5 (27) 0.008 
Intubated 42.9, (12) 9.7 (7) 0.0004 
Expired 32.1 (9) 4.2 (3) 0.0004 

Patients with moderate- or high-risk TA-TMA were compared with patients without TA-TMA, according to criteria developed by Jodele et al.1,11,15,20  All complications occurred after stem cell infusion. Complications in the moderate- or high-risk TA-TMA group occurred either after TA-TMA diagnosis (but within 1 year of diagnosis) or within 2 weeks before TA-TMA diagnosis. Complications that occurred more than 2 weeks before TA-TMA diagnosis were excluded from the moderate or high-risk TA-TMA group. Clinical concern for seizure was determined based on clinician documentation in patient charts. P values were generated by Fisher’s exact test. EEG, electroencephalogram, ICU, intensive care unit. 2. Bold values indicate values that were statistically significant with a P value cutoff of < 0.05.

or Create an Account

Close Modal
Close Modal